Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19288763 | 0.96 | GRIN1 (0.38) | GRIN1GRIN2A | |
| SCHEMBL16219931 | 0.93 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL19937579 | 0.93 | CHRM2 (0.34) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL3928323 | 0.93 | CHRM2 (0.34) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL27589544 | 0.91 | GRIN1 (0.35) | GRIN1GRIN2A | |
| SCHEMBL24702209 | 0.89 | GRIN1 (0.33) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL18207791 | 0.89 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL17327469 | 0.89 | GRIN1 (0.33) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL937953 | 0.86 | HRH4 (0.35) | GRIN1GRIN2A | |
| SCHEMBL8232360 | 0.86 | HRH4 (0.35) | GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | GRIN1 1328/4885GRIN2A 1112/4885CHRM2 38/4885 |
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | RPL5, RPL35, HAVCR2 | GRIN1 1064/4885GRIN2A 1637/4885CHRM2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.